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Abstract
Epsilonproteobacteria is a large group of Gram-negative curved or spiral microaero-
philic rods, of which many are difficult to culture. Because this group of bacteria is 
not very well investigated, our knowledge about them is limited, and a great amount 
of research is still needed. At least two species are well-established human pathogens: 
Campylobacter jejuni/coli causing gastroenteritis and Helicobacter pylori causing gastric 
and extra-gastric manifestations. It is well accepted that H. pylori causes a chronic inflam-
mation in the stomach and thereby causes H. pylori-associated gastritis, which may or 
may not be symptomatic. The association between H. pylori and peptic ulcers, MALT 
lymphomas, gastric cancer, idiopathic thrombocytopenic purpura, and unexplained 
iron-deficiency anemia (IDA) is strongly evidence based. On the other hand, pernicious 
(vitamin B12 deficiency) anemia, neuromyelitis optica, asthma, and Graves’ disease are 
less evidence based. H. pylori may also be associated with cardiovascular disease, pan-
creatitis, pancreatic cancer, obesity, diabetes mellitus type 2, Parkinson’s disease, liver 
diseases, and preeclampsia. H. pylori is thus involved in many gastric and extra-gastric 
manifestations either directly or indirectly by several proposed mechanisms including 
antigenic mimicry.
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1. Introduction
Epsilonproteobacteria is a large group of Gram-negative curved or spiral rods which include the 
genera Campylobacter spp., Helicobacter spp., Arcobacter spp., and Wolinella spp. (Table 1) [1]. The 
bacteria have microaerobic or anaerobic growth requirements, and many of these are difficult 
to culture from clinical samples [2]. Recent studies with identification of Epsilonproteobacteria 
by PCR have shown that these bacteria cause infections in humans more commonly than 
previously thought [3, 4]. The most well-known species are Campylobacter jejuni/coli causing 
gastroenteritis [2] and Helicobacter pylori causing gastric and extra-gastric manifestations [5].
This chapter will focus on Helicobacter spp. and mainly on H. pylori. Helicobacter spp. can be 
divided into three groups: (1) gastric Helicobacter spp., (2) intestinal Helicobacter spp., and (3) 
hepatobiliary Helicobacter spp. [6]. The knowledge about intestinal Helicobacter spp. in human 
diseases is very limited mainly because they are very difficult to culture. In contrast to the 
intestinal and hepatobiliary Helicobacter spp., the gastric Helicobacter spp. produce a great 
amount of urease, which is important for its survival in the stomach by neutralizing acid, 
thereby creating a neutral microenvironment [7]. Urease is also crucial for the bacteria’s sur-
vival through antigenic shedding where urease captures human antibodies [8]. The human 
gastric Helicobacter sp., H. pylori, is the most intensively investigated Helicobacter sp., but gas-
tric Helicobacter spp. from animals (Helicobacter heilmannii, Helicobacter bizzozeronii, Helicobacter 
suis, etc.) have also been found in the human stomach [9]. These bacteria colonize the stom-
ach in very different ways. H. pylori colonizes the antrum part of the stomach on the surface 
between epithelial cells and can actively move down between the epithelial cells [10]. On the 
other hand, Helicobacter sp. from animals colonizes the parietal cell glands in the corpus/fun-
dus part of the stomach which may contribute to other manifestations than those caused by 
H. pylori [11]. Usually, a stronger cellular immune response is seen in H. pylori in comparison 
to the animal-associated Helicobacter spp. [11].
Genus Species
Arcobacter anaerophilus, aquimarinus, bivalviorum, butzleri, cibarius, cloacae, cryaerophilus, defluvii, ebronensis, 
ellisii, haliotis, halophilus, lanthieri, lekithochrous, marinus, molluscorum, mythili, nitrofigilis, 
pacificus, suis, thereius, trophiarum, venerupis
Campylobacter avium, canadensis, coli, concisus, corcagiensis, cuniculorum, curvus, fetus subsp. fetus, fetus 
subsp. testudinum, fetus subsp. venerealis, geochelonis, helveticus, hepaticus, hominis, hyoilei, 
hyointestinalis subsp. hyointestinalis, hyointestinalis subsp. lawsonii, iguanorium, insulaenigrae, 
jejuni subsp. doylei, jejuni subsp. jejuni, lanienae, lari subsp. concheus, lari subsp. lari, mucosalis, 
ornithocola, pyloridis, pinnipediorum, pinnipediorum subsp. caledonicus, pinnipediorum subsp. 
pinnipediorum, rectus, showae, sputorum, subantarcticus, upsaliensis, ureolyticus, volucris
Helicobacter acinonychis, ailurogastricus, anseris, apri, aurati, baculiformis, bilis, bizzozeronii, brantae, 
canadensis, canicola, canis, cetorum, cholecystus, cinaedi, cynogastricus, equorum, felis, fennelliae, 
ganmani, heilmannii, hepaticus, himalayensis, jaachi, japonicus, macacae, marmotae, mastomyrinus, 
mesocricetorum, muridarum, mustelae, pamatensis, pullorum, pylori, rodentium, salomonis, saguini, 
suis, trogontum, typhlonius, valdiviensis
Wolinella succinogenes
Table 1. The species belonging to the four largest groups of Epsilonproteobacteria [102].
Helicobacter Pylori - New Approaches of an Old Human Microorganism14
H. pylori may either cause direct or indirect damage to the stomach: direct damage where 
H. pylori infections disintegrate gastric mucosa and cause apoptosis through cytotoxin-
associated gene A (CagA) and vacuolating toxin (VacA) or indirect damage where H. pylori 
induces a strong and chronic immune response by activating B and T lymphocytes, macro-
phages, neutrophilic lymphocytes, and probably also eosinophil leukocytes. T cell-activated 
B lymphocytes, regulatory T cells (Treg), and T helper 17 cells (Th17) are some of the B and 
T lymphocytes that are important in H. pylori infections. T cell-activated B lymphocytes are 
responsible for a strong humoral immune response primarily toward H. pylori urease, flagella, 
CagA, and VacA. These activated B and T lymphocytes release a large range of cytokines of 
which IL1-β, TNF-α, INF-γ, IL6, IL-8, IL-10, IL-17, and cyclooxygenase-2 (COX-2) are the most 
important cytokines in severe H. pylori infections [12, 13].
Many microorganisms can cause autoimmune diseases. The mechanisms involved include 
molecular mimicry (when bacterial antigens cross-react with human tissue), epitope spread-
ing, bystander effect, microbial superantigens, immune complex formation, MHC class 
II expression on nonimmune cells, and high levels of pro-inflammatory cytokines [14–17]. 
H. pylori has been implicated in both organ-specific and non-organ-specific autoimmune 
diseases and has been investigated sporadically or systematically in 95 autoimmune-related 
diseases [18]. Many mechanisms underlying the antigenic mimicry between H. pylori and the 
host have been proposed. Efforts have been made to identify homologous sequences between 
H. pylori and host polypeptides. H+/K + −adenosine triphosphatase, Lewis antigens, and lipo-
polysaccharide seem to be autoantigens in autoimmune gastritis. Glycoproteins and Lewis 
antigens may be autoantigens directed against platelets in idiopathic thrombocytopenic pur-
pura (ITP). Lewis antigens, heat shock protein 60 (HSP60), and 160/180 kDa antigens appear to 
be autoantigens to the endothelium, while alpha-carbon anhydrase and plasminogen-binding 
proteins could to be autoantigens in the pancreas [13].
All in all, H. pylori can cause both gastric and extra-gastric diseases through a complex mecha-
nism involving both host and bacterial factors.
2. Gastritis and peptic ulcer
Whenever H. pylori is found in the human stomach, there is never just a simple colonization. 
Instead, there is always a cellular and humoral immune response confirming that H. pylori 
causes infection [10, 19, 20]. Thus, patients with gastritis and H. pylori have H. pylori-related 
gastritis. However, if there is no H. pylori infection, patients may have functional gastritis but 
no inflammation. H. pylori-related gastritis may benefit from antibiotic treatment, whereas 
there is no indication for antibiotic treatment for functional gastritis [21].
Peptic ulcers occur in about 10% of patients infected with H. pylori where most (80%) are duo-
denal ulcers [19]. More than 90% of duodenal ulcers are caused by H. pylori [19]. The patho-
genesis of these ulcers is not clear, but they often occur in the part of the duodenum where the 
flow from the stomach content is the highest. Duodenal ulcers may be caused by a combina-
tion of physical, physiological, and immunologic effects as well as H. pylori. Patients with 
duodenal ulcers almost always benefit from antibiotic treatment. More than 60% of gastric 
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ulcers are caused by H. pylori, while the remaining 40% may be caused by different sources 
such as medication (NSAID, etc.) [21, 22]. Gastric ulcers are often found in the isthmus area of 
the stomach where the amount of blood flow of the stomach is the lowest. H. pylori stimulates 
the production of platelet-activating factor (PAF) which acts on angiogenesis by contracting 
blood vessels [23]. H. pylori has a direct damaging effect on the epithelium and interferes with 
the immune system in many ways [24]. However, the mechanisms are very complex, and the 
pathogenesis is still not completely understood.
3. Mucosa-associated lymphoid tissue (MALT) lymphomas
MALT lymphomas are a group of lymphomas which arise in the tissue normally devoid 
of lymphoid tissue, such as the stomach. These tissues accumulate lymphoid tissue during 
chronic antigenic stimulation such as chronic infections and autoimmune diseases. H. pylori 
causes about 80% of low-grade MALT lymphomas and 60% of high-grade MALT lymphomas 
[19]. Eradication of H. pylori stops the progression in most cases, and 60–80% of early-state 
low-grade MALT lymphomas will regress [25]. The mechanism by which H. pylori induces 
MALT lymphomas is unclear, and there is no evident correlation between MALT lymphomas 
and H. pylori virulence factors [26]. One theory is that the development of gastric MALT lym-
phomas in patients with H. pylori could be secondary to chronic antigenic stimulation of the 
immune system by the pathogen [27]. However, as in many other diseases, antigenic mimicry 
may also play a role [27]. Finally, it is possible that MALT lymphomas are correlated to non-
pylori Helicobacter spp. instead of H. pylori [28, 29].
4. Gastric cancer
H. pylori causes approximately 80% of all gastric cancer cases, and in 1994 H. pylori became cat-
egorized as a Group 1 carcinogen meaning that H. pylori is a definite carcinogen to humans [30].
The development of gastric cancer is a complex process that depends on H. pylori virulence 
factors, host mucosa properties, immunological reactions to infections, as well as environmen-
tal factors in the stomach. In H. pylori, virulence factors like CagA and VacA have been sug-
gested to influence cancer development. CagA gene and the type IV secretion system (T4SS) 
are encoded by a 40-kb DNA fragment called cag pathogenicity island (cagPAI) [19, 31]. CagA 
protein infects host gastric epithelial cells via the T4SS, where it is tyrosine-phosphorylated 
by host kinases at specific glutamate-proline-isoleucine-tyrosine-alanine (EPIYA) motifs [31, 
32]. CagA thereafter interferes with different host cell-signaling pathways causing changes in 
cell growth, polarity, and motility, thereby increasing the risk for gastric cancer [19, 32]. VacA 
toxin affects gastric epithelial cells in a similar manner by affecting the host’s inflammatory 
response as well as cellular apoptosis among other ways [19]. Other host factors could be 
high-salt diets and iron deficiency, which have been proven to increase the risk for gastric 
cancer [33, 34].
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If H. pylori is treated in the early premalignant stages (atrophic gastritis), further cancer 
development can be prevented [35]. If intestinal metaplasia has developed, it is believed that 
antibiotic treatment has no effect [21]. As with gastritis and peptic ulcers, the relationship 
between H. pylori and gastric cancer has many loose ends that need to be explained before we 
can completely understand the process.
5. Idiopathic thrombocytopenic purpura (ITP)
Idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura (ITP) is an 
acquired autoimmune disease resulting in the destruction of antibody-covered platelets and 
decreased platelet production. This results in an increased risk for bruising and bleeding. ITP 
is defined as a platelet count <100 × 109 /L, may be either primary or secondary, and is classi-
fied as acute, persistent, or chronic [36].
The mechanism that leads to ITP in H. pylori-infected patients is not entirely established. It 
is proposed that molecular mimicry may be involved [13]. Cross-reactivity between plate-
let-associated immunoglobulin G and CagA has been found, which suggests that mimicry 
through CagA may play a role in the development of ITP [37].
It is well established that H. pylori screening may be warranted in patients with ITP. A system-
atic review from 2009 with 696 evaluable patients found that in patients with H. pylori infec-
tion, eradication of the bacteria led to a complete treatment response in 43% of the patients and 
an overall response (platelet count ≥30 × 109/L and at least a doubling of initial platelet count) 
of 50%. The treatment tended to be more effective in milder forms of thrombocytopenia. The 
authors found that the predictors of treatment response were quite heterogeneous from study 
to study. Shorter duration of ITP was consistently found, and response rates tended to be 
higher in countries with a higher prevalence of H. pylori [38]. In the highly H. pylori prevalent 
country of South Korea, a more recent prospective study with 26 patients with persistent or 
chronic ITP investigated the efficacy of H. pylori eradication as a first-line treatment in patients 
with moderate thrombocytopenia [39]. The study found an eradication rate of 80% and a 
maximal complete response rate of 65% [39].
The most recent ITP guidelines from the American Society of Hematology (ASH) recommend 
eradication therapy in adult ITP patients with H. pylori infection. They do not define which 
patients should be screened or at what point in the course of the illness patients should receive 
treatment [36]. ASH recommends against routine testing in children because of diverging 
results but rather argues for the consultation with a pediatric gastroenterologist beforehand. 
Since the publication of the ASH guidelines, a randomized-controlled trial (RCT) with 85 
ITP-affected children has been published. Twenty-two children were H. pylori infected, and 
they were randomized to receive either eradication therapy or no therapy. Complete response 
was achieved in 60% of the treated children compared to 18% of the children who were not 
treated. The authors suggested that H. pylori infection may play a bigger role in the pediatric 
ITP population than the earlier notions. It is also noted that 86% of the patients had CagA 
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antibodies and 82% harbored VacA antibodies [40]. The recently updated joint European 
Society for Pediatric Gastroenterology, Hepatology, and Nutrition/North American Society 
for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN/NASPGHAN) guide-
lines recommend testing for H. pylori in children with chronic ITP [41].
6. Iron-deficiency anemia
H. pylori infection has also been linked to iron-deficiency anemia (IDA) [42–44]. Mechanisms 
that cause IDA may increase iron loss due to hemorrhagic gastritis, gastric cancer, peptic 
ulcers, iron utilization for bacterial growth, achlorhydria resulting in reduced iron uptake, 
and reduced secretion of ascorbic acid [45].
A meta-analysis comprising 15,183 patients from 20 studies found an association between H. 
pylori infection and IDA (odds ratio (OR) 2.22) [46]. They also found a greater effect of eradica-
tion therapy plus iron than iron supplements alone but with heterogeneous results. Adult 
IDA patients reacted more strongly to eradication than children and adolescents, and bismuth 
triple therapy seemed to be more effective than proton pump inhibitor (PPI) triple therapy. 
The authors do not recommend a population-based screening for H. pylori to prevent IDA [46].
On the other hand, Herschko et al. studied 160 patients with autoimmune gastritis, of whom 
83 presented with IDA [47]. When stratifying by age, they found a decreasing prevalence of 
coexistent H. pylori infection with increasing age: 88% at age <20 years, 47% at 20–40 years, 
38% at 41–60 years, and 13% at age >60 years. A possible explanation, which other authors 
also have mentioned, is that H. pylori demands an acidic environment to survive, which no 
longer exists in advanced atrophic anemia. This might suggest that H. pylori infection in auto-
immune gastritis may represent an early phase of the disease in which an infectious process is 
gradually replaced by an autoimmune disease terminating in a burned-out infection and the 
irreversible destruction of gastric mucosa. This might explain why younger patients with IDA 
have a high prevalence of H. pylori infection [47].
The British Society of Gastroenterology recommends noninvasive testing and antibiotic 
treatment for H. pylori in patients with IDA and normal esophagogastroduodenoscopy and 
colonoscopy [48]. The American College of Gastroenterology also recommends testing for H. 
pylori in patients with unexplained IDA [49]. The association between IDA and H. pylori infec-
tion in the pediatric population is less studied and with heterogeneous results. ESPGHAN/
NASPGHAN guidelines propose that in children with refractory IDA where there is an indi-




Vitamin B12 (cobalamin) deficiency is estimated to affect approximately 10–15% of the popula-
tion older than 60 years. There are several causes where pernicious anemia and food-cobala-
min malabsorption are the most common reasons. Cobalamin is obtained primarily from food 
through a complicated process where an acidic environment releases cobalamin from food 
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and thereafter binds to intrinsic factors secreted from parietal cells and finally is absorbed by 
specific receptors in the terminal ileum. Pernicious anemia is an autoimmune disorder con-
sisting of chronic atrophic gastritis, decreased acid secretion, and antibodies directed against 
parietal cells and/or intrinsic factors, thereby leading to decreased cobalamin absorption. 
H. pylori possibly stimulates these antibodies directed against parietal cells/intrinsic factors, 
thereby inducing pernicious anemia. In food-cobalamin malabsorption, there is an inability 
to absorb food-bound or protein-bound cobalamin in a person that normally can absorb free 
cobalamin. H. pylori infection predisposes to a more severe form of food-cobalamin malab-
sorption [50].
As mentioned above, it has been proposed that B12 deficiency can arise as the result of a late 
phase of H. pylori-induced atrophic gastritis [47]. This theory has been mentioned already in 
the early 1990s [51]. In a prospective case series with 138 patients with megaloblastic anemia 
and low cobalamin, it was found that 56% had H. pylori infection. Eradication therapy was 
successful in 40% of the infected patients, and the hematological parameters and B12 levels 
improved in all these patients without complementary cobalamin therapy [52].
The literature regarding the association between H. pylori and pernicious anemia shows more 
heterogeneous results than for ITP and IDA [52]. Therefore, treatment guidelines do not yet 
recommend screening for H. pylori in pernicious anemia. However, the Maastricht V/Florence 
Consensus Report does recommend that in all three of the abovementioned disorders H. pylori 
should be screened for and eradicated [21].
8. Cardiovascular disease
Studies indicate an association between H. pylori and cardiovascular disease (CVD) [53, 54]. 
However, the stratification of patient groups and methods are very heterogeneous which may 
be the reason for the very diverging results in the studies [53]. H. pylori seems to mostly be 
associated with coronary atherosclerosis [55, 56]. This is in accordance with an unpublished 
study where we found increased antibodies to H. pylori, but not to Chlamydophila pneumoniae 
and Cytomegalovirus in patients undergoing surgery for coronary atherosclerosis. H. pylori can 
survive in monocytes, and it might be speculated whether the bacteria could be transferred 
from the stomach to the coronary vessels. Here, H. pylori may stimulate PAF and other factors 
that may act on angiogenesis [23, 56]. H. pylori may also stimulate the atherogenesis through 
molecular mimicry or vitamin B12 and folate malabsorption [13, 53, 54]. In addition, H. pylori 
may change the lipid profile by increasing LDL levels and decreasing HDL levels as seen in 
many other infections, which leads to atherogenesis [53, 54, 57–59].
9. Pancreatitis and pancreatic cancer
Studies have shown a correlation between increased antibody levels to H. pylori in patients 
with pancreatitis and pancreatic cancer [60–63]. In an unpublished study, we showed that in 
more than 50% of patients with pancreatitis H. pylori was cultured from the antral part of the 
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stomach. The interaction leading to pancreatic cancer is unknown, but H. pylori infection in 
the antral part of the stomach decreases the production of somatostatin. This increases pan-
creatic bicarbonate and secretin which stimulates ductal epithelial cell proliferation [64]. In 
addition, studies indicate that H. pylori increases the risk of autoimmune pancreatitis through 
molecular mimicry and thereby increases the risk for pancreatic cancer [13, 60, 63–65]. These 
findings are of great interest and need further intensive research.
10. Obesity and diabetes mellitus type 2
Obesity is becoming a worldwide problem, and population studies have shown that in the 
same areas where the prevalence of H. pylori is decreasing, the prevalence of obesity is increas-
ing [21, 66]. An implication of obesity could be diabetes mellitus type 2. A possible mechanism 
in which H. pylori affects obesity and thereby also affects type 2 diabetes is persistent damage 
of gastric mucosa, e.g., chronic gastritis. This might affect ghrelin production, thereby chang-
ing food intake and increasing body weight [67, 68].
Ghrelin is a hormone mainly produced by endocrine cells in the gastrointestinal mucosa and 
is released to the surroundings. This molecule is important for stimulating food intake and 
weight gain [69]. The damages that H. pylori introduce on gastric mucosa reduce the number 
of ghrelin-producing cells and decrease plasma ghrelin concentrations significantly, thereby 
reducing the feeling of satiety which can lead to obesity [67, 68, 70].
Ghrelin also seems to play a role in fat metabolism and glucose homeostasis, which can lead 
to a cross-reaction between lipid and glucose metabolisms that may result in insulin resis-
tance [71]. However, one thing is clear, diabetes mellitus type 2 is a multifactorial disease, and 
H. pylori is only one of the many risk factors. H. pylori may also act on leptin or by activating 
cytokines that together can have an effect on insulin secretion [72, 73].
Although many studies have shown that there could be a correlation between H. pylori and 
obesity and diabetes mellitus type 2, other studies have shown that there are none and the 
correlation is still uncertain [66, 74].
11. Parkinson’s and Alzheimer’s diseases
Numerous studies indicate that H. pylori infection is associated with a more rapid devel-
opment of cognitive and functional deterioration. Furthermore, eradication of H. pylori 
could give an improved disease severity [75–78]. Also, a study by Weller et al. showed that 
the presence of CagA antibodies is associated with a poorer Parkinson’s prognosis [79]. 
It is proposed that H. pylori initiates the destruction of mitochondria and together with 
antigenic mimicry stimulates Parkinson’s disease [72]. Only few studies focus on H. pylori 
and Alzheimer’s disease, and they are too preliminary to show a causal or therapeutic 
association [72, 75].
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12. Neuromyelitis optica
Several studies have shown a correlation between H. pylori and neuromyelitis optica (NMO) 
[18]. NMO is a disease where antibodies attack aquaporin-4 on astrocytes in the central ner-
vous system [80]. There is a close relationship between H. pylori and antibodies to aquapo-
rin-4, and thus molecular mimicry could play a role [18].
13. Asthma
The prevalence of asthma is increasing in areas where the prevalence of H. pylori is decreasing 
[81]. Meta-analyses have found an inverse correlation between H. pylori and asthma, but the 
mechanism is unclear [72, 82, 83]. CagA-positive H. pylori strains especially have been found 
to have a greater inverse relationship with asthma than those without H. pylori [81]. The long-
established hygiene hypothesis, where a lack of exposure to infectious agents leads to an 
increased risk for allergens, has been proposed as one way in which an absence of H. pylori 
causes asthma [82]. Th2-mediated immune responses drive allergies, while Th1-mediated 
immune responses inhibit these reactions. H. pylori appears to stimulate Th1-mediated immune 
responses but inhibit Th2-mediated immune responses through neutrophil-activating protein 
(HP-NAP), thereby inhibiting asthma development [84]. Another possible mechanism of H. 
pylori is upregulation of Treg cells which can control Th2-mediated immune responses [82]. 
A mouse study by Arnold et al. proved that H. pylori infection protected mice against asthma 
and an upregulation of Treg cells was found in mice infected with H. pylori [85]. Thus, H. pylori 
could inhibit asthma in a multitude of ways.
14. Hepatobiliary diseases
Non-pylori Helicobacter species have been isolated from the liver of a variety of animals. H. 
hepaticus, H. bilis, and H. cholecystus are involved in the pathogenesis of chronic liver diseases 
and liver carcinomas [86–88]. H. pylori, H. hepaticus, H. bilis, and H. cholecystus have been 
detected in the human hepatobiliary tissue mainly by PCR [89–91]. Several studies have shown 
an increased prevalence of H. pylori in patients with hepatocellular carcinomas (HCC), liver 
encephalopathy (HE), liver fibrosis, cholangiocarcinoma (CCA), primary biliary cirrhosis 
(PBC), and primary sclerosing cholangitis [92]. Much interest has been linked to HCC and CCA 
which histologically is characterized as adenocarcinomas. The pathogenesis has been proposed 
to follow the same pattern as in stomach cancer: hyperplasia, metaplasia, dysplasia, and lastly 
cancer [92]. Inflammatory cytokines and chemokines may play an important role in the patho-
genesis. HE is a frequent complication to liver cirrhosis with a wide variety of neuropsychi-
atric symptoms, and high levels of ammonia play an important role in the pathogenesis [93]. 
H. pylori produces urease which reacts to ammonium, which might explain a possible mechanism 
in HE development. Liver fibrosis, among other ways, may be caused by H. pylori stimulating 
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hepatocytes and results in accumulation of collagen, thereby causing fibrosis [63]. Some of the 
risk factors for these cancers are population genetics, geographical and environmental factors, 
cholelithiasis, obesity, chronic inflammation, and obstruction of the bile duct [92, 94].
15. Autoimmune thyroid diseases
Both Graves’ disease and Hashimoto’s thyroiditis are autoimmune diseases in the thyroid. 
Graves’ disease is characterized by hyperthyroidism and an enlarged gland, while Hashimoto’s 
thyroiditis is characterized by hypothyroidism and the destruction of thyroid tissue. There is 
an association between Graves’ disease and H. pylori, where CagA is most likely an impor-
tant virulence factor [95]. A study by Bassi et al. showed that 82% (43/52) of patients with 
Graves’ disease were positive for H. pylori, where 84% (36/43) of H. pylori-positive Graves’ 
disease patients were positive for CagA antigens. Also, a different study by Bertalot et al. 
showed a reduction in thyroid autoantibodies following H. pylori eradication [96]. Amino 
acid sequences of thyroid peroxidase and CagA are very similar, and cross-reactivity is a 
possible mechanism by which H. pylori increases the risk of developing Graves’ disease [18, 
95]. In addition, Graves’ disease is often found with other autoimmune diseases which may 
reflect the ability of H. pylori to induce multiple autoimmune diseases simultaneously [97]. 
However, the same cannot be said about Hashimoto’s thyroiditis where a significant associa-
tion between Hashimoto’s thyroiditis and H. pylori was not found by Bassi et al. [95].
16. Preeclampsia
The first study investigating the association between H. pylori infection and preeclampsia (PE) 
was conducted in Italy and published in 2006 [98]. It was found that 32% of women with a nor-
mal pregnancy harbored anti-H. pylori antibodies compared to 51% of preeclamptic women. 
The difference was even bigger when looking at the presence of anti-CagA antibodies: 15 vs. 
81% in women with a normal pregnancy vs. preeclamptic women. The authors concluded that 
the increased inflammatory activity in H. pylori-infected patients may contribute to the devel-
opment of PE, especially in CagA strains. Interestingly, no H. pylori DNA was present in the 
placentas that were studied, and therefore the inflammation is probably not locally induced.
A review from 2014 concluded that there is evidence indicating that H. pylori negatively influ-
ences human reproductivity, including PE [99]. This is probably due to both increased inflam-
matory activity and antigenic mimicry with CagA-positive strains appearing to be the most 
important culprits [99]. A recent meta-analysis of observational studies with 9787 women 
(879 preeclamptic) confirmed these theories, with an OR of 2.32 for anti-H. pylori antibodies in 
cases compared to controls and an OR of 3.97 for having anti-CagA antibodies in preeclamp-
tic patients [100]. A review on the topic of infections and the risk of PE mentions H. pylori as 
a possible cause of PE and recommends that screening (and treatment) of known infectious 
organisms causing PE should be included in antenatal programs [101]. However, as men-
tioned by Bellos et al., it is yet unknown if H. pylori predisposes to mild or severe PE, at which 
gestational age optimal screening should be conducted, and most importantly how effective 
eradiation is in terms of reducing the incidence and severity of PE [100].
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17. Discussion
H. pylori can induce many pathogenic reactions in infected individuals. There are mainly 
three different ways H. pylori acts. (1) The bacteria have several virulence factors (Cag PAI, 
Vac A, etc.) that can cause direct damage and apoptosis of epithelial cells in the stomach and 
can stimulate mast cells to liberate PAF which affects the angiogenesis in the stomach. This 
may be some of the main actions on gastric diseases such as peptic ulcers and gastric cancer 
(Figure 1). (2) There is a strong cellular and humoral immune response to H. pylori with the 
release of different cytokines and chemokines. Cytokines and chemokines subsequently react 
both in the stomach and in extra-gastric organs (Figure 2). In addition, several H. pylori anti-
gens are structurally like antigens of the human body and therefore may cause cross-reactions 
(antigenic mimicry) (Figure 3). All these pathogenic mechanisms of H. pylori may result in 
different diseases both in the stomach and in extra-gastric organs.
The role of H. pylori in relation to gastritis, peptic ulcers, MALT lymphomas, and gastric can-
cer is well known and established. However, there is confusion about the difference between 
Figure 1. The roles of the main virulence factors in pathogenesis of Helicobacter pylori infection [6]. Adherence of 
Helicobacter pylori to gastric epithelial cells is mediated by BabA and SabA binding Leb and Lewis x/a, respectively. 
CagA is translocated into epithelial cells through T4SS and then tyrosine-phosphorylated at EPIYA sites by Src and 
Abl kinases. CagA contributes to alteration of myriad signaling transduction, which affects host cell physiology with 
disruption of intercellular junctions, loss of cell polarity, promotion of inflammation, dysregulation of cellular apoptosis, 
and proliferation. VacA inducts cytoplasmic vacuolation, apoptosis, and immune suppression [6, 103].
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functional dyspepsia and H. pylori-induced gastritis even though H. pylori is always followed 
by a strong cellular and humoral immune response and fulfills the criteria for a true infection.
As with many other infections, H. pylori infection does not always cause symptoms. The 
evidence-based associations between H. pylori and ITP and unexplained IDA are less well 
known. Patients with these diseases should be tested for H. pylori. There are slightly weaker 
associations found between H. pylori and B12 deficiency anemia, neuromyelitis optica, and 
Graves’ disease, and patients with these diseases should also be tested for H. pylori [21].
Weaker associations between H. pylori and cardiovascular disease, pancreatic cancer, pancre-
atitis, obesity and type 2 diabetes, Parkinson’s disease, asthma, liver diseases, and preeclamp-
sia have been found. H. pylori possibly causes these diseases through antigenic mimicry, and 
affected patients should be considered for H. pylori testing.
In conclusion, a variety of diseases may be caused by H. pylori, and affected patients should 
be tested for H. pylori. However, further larger and more well-designed studies with better 
stratification of patients and better diagnostics of H. pylori are needed.
Figure 2. The inflammatory response in Helicobacter pylori infection. Immune cells are recruited to the lamina propria of 
the gastric epithelium by chemokines and cytokines (IL-8, MCP-1, GRO-α, IL-1β, TNF-α) produced by epithelial cells or 
directly by bacterial products including H. pylori neutrophil-activating protein, VacA, and urease. At the site of infection, 
the immune cells are activated and exert their effector functions, including the production of cytokines (IL-1β, TNF-
α, IL-6, IL-12, IFN-γ), chemokines (IL-8, MCP-1), proteolytic enzymes, oxide nitric (NO), and reactive oxygen species 
(ROS). PG, peptidoglycan; T4SS, type IV secretion system; IL, interleukin; TNF, tumor necrosis factor; MCP, macrophage 
chemotactic protein; GRO, growth-regulated oncogene [104].
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18. Conclusion
A variety of diseases are may be caused by H. pylori; some such as peptic ulcer and gastric 
cancer by a direct effect on the gastric epithelial cells cause cell damage and apoptosis. The 
complex immune response to H. pylori contributes to the pathogenesis such as mast cells 
liberating PAF which affect the angiogenesis in the stomach. The complex immune response 
to H. pylori is also involved in the pathogenesis of extra-gastric manifestations of H. pylori 
infection. In addition to the immune response to H. pylori, H. pylori also contains a lot 
of antigens which cross-react with human antigens (antigenic mimicry) that is responsible 
for many autoimmune diseases such as thrombocytopenia purpura, B12 deficiency anemia, 
neuromyelitis optica, Graves’ disease, etc. Thus, H. pylori causes or may cause a lot of well-
known and less well-investigated diseases, and these patients should be tested for H. pylori. 
However, many of these diseases are rather rare especially in children that need larger, and 
more well-designed multicenter studies with better stratification of patients and better diag-
nostics of H. pylori for prober studies are needed. In addition, little is known about the exact 
virulence and pathogenic mechanisms of H. pylori, and basic research in these diseases is 
urgently needed.
Figure 3. Hypothesis of autoimmune disorders due to molecular mimicry between Helicobacter pylori and the host 
components. Chronic exposure of the host immune system to Helicobacter pylori (H. pylori) components that have 
homologous sequences with the host cellular or soluble compounds may initiate the production of autoantibodies. 
However, how often the autoantibodies arising during H. pylori infection are involved in various post-infectious 
pathologies should be elucidated. The graph shows the examples of host targets for the antibodies induced by H. pylori 
components. GP, glycoproteins; HSP, heat shock protein; H+/K+ ATPase, H+/K + −adenosine triphosphatase; HLA, 
human leukocyte antigens; CCRL1, CC chemokine receptor-like 1; Le, Lewis antigens [105].
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